AI assistant
EKF DIAGNOSTICS HOLDINGS PLC AGM Information 2021
7617_agm-r_2021-05-19_a33534a3-2ec2-4e21-bbd5-11e89aab43b5.html
AGM Information
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 1742Z
EKF Diagnostics Holdings PLC
19 May 2021
EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")
Result of AGM
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed point-of-care business, announces that at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.
The results of the AGM will be made available on the Company's website: https://www.ekfdiagnostics.com/
| EKF Diagnostics Holdings plc | www.ekfdiagnostics.com | |
| Christopher Mills, Non-executive Chairman | Tel: +44 (0) 29 2071 0570 | |
| Julian Baines, CEO | ||
| Richard Evans, FD & COO | ||
| N+1 Singer | Tel: 020 7496 3000 | |
| Aubrey Powell / George Tzimas / Tom Salvesen | ||
| Walbrook PR Limited | Tel: +44 (0) 20 7933 8780 or [email protected] | |
| Paul McManus / Lianne Cawthorne | Mob: +44 (0) 7980 541 893 / +44 (0) 7584 391 303 | |
About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)
EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analysers in regular use across more than 100 countries. EKF specialises in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analysers.
EKF specialises in the development, production and worldwide distribution of point-of-care analyzers and clinical chemistry reagents for use in hospital and research laboratories, doctor's offices, blood banks and for in-field anaemia screening programmes. EKF is also a bulk manufacturer of enzymes and has custom manufacturing facilities in the USA for a variety of life science products.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RAGSFIFFUEFSEII